Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO Net Product Revenues of $153 Million in Q1'24 (+74% Y/Y); Children Treated Increased Over 100% Y/Y For Full-year 2024 Guidance, Total Revenues Reaffi ...

Investors are always looking for stocks that are poised to beat at earnings season and BioMarin Pharmaceutical Inc. (BMRN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because BioMarin is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pre ...

Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN) will announce quarterly earnings of $0.60 per share in its forthcoming report, representing no change year over year. Revenues are projected to reach $649.75 million, increasing 8.9% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company announ ...

SAN RAFAEL, Calif., April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-330-3556International Dial-in Number: 646-960-0826Conference Call ID: 1816377 U.S. / Canada Replay Dial-in Numbe ...

Although many popular biotech stocks peaked in 2020 and early 2021 and then started to decline, early 2024 has seen signs of recovery and a return of investors’ trust. Nonetheless, this biotech stock powered through the period, achieving miracle growth and maintaining its decades-long tradition of positive returns.The biotech stock in today’s limelight is BioMarin Pharmaceutical (NASDAQ: BMRN), a biotechnology and pharmaceutical company focusing on tackling rare genetic diseases through an innovative portfo ...

Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer. Ms. Hubbard is a proven leader who brings to ...

-       Cowen 44th Annual Healthcare Conference on March 5-       Leerink Partners Global Biopharma Conference on March 11-       Jefferies Biotech on the Bay Summit on March 12-       Barclays 26th Annual Global Healthcare Conference on March 12 SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March. Cowen 44th Annual Healthcare Conference (Boston, MA) Tuesday, March ...

BRINEURA is approved for marketing in the U.S. (for ages three and older) and in the EU (for all ages from birth) and in other international markets. ALDURAZYME ALDURAZYME is a highly purified protein that is designed to be identical to a naturally occurring form of the human enzyme alphaL-iduronidase, a lysosomal enzyme normally required for the breakdown of GAGs. MPS I is a progressive and debilitating life-threatening genetic disease that is caused by the deficiency of alpha-L-iduronidase. Patients with ...

MOST PRODUCTIVE Continued significant revenue growth, intense focus on operational excellence, 6 Total Revenues of $646.2 million in the Fourth Quarter 2023 Increased 20% Q/Q Produced double-digit revenue growth and significant operating leverage in 2023, with non-GAAP diluted earnings per share increasing 36% Y/Y B:OMARIN (2) Non-GAAP Income is defined by the company as reported GAAP Net Income, excluding amortization expense, stock-based compensation expense, contingent consideration, and, in certain peri ...

Operator Luca Issi Given the relatively slow launch, is that still a plan? Or is there a scenario don't invest that capital, just you prioritize operational efficiency to really make the story here, driven primarily by VOXZOGO [indiscernible] and valrox any color there, much appreciated. We do intend to include a review of those studies in our portfolio assessment and prioritization. And so we'll communicate the plans for each of the additional potential Operator This concludes today's call. You may now dis ...